The Federal Trade Commission has accused several drugmakers of violating antitrust laws, via agreements the commission said delayed the U.S. launches of cheaper generic versions of two popular pain treatments. It's the first so-called "pay for delay" case brought by the commission in which a drug's original maker agreed not to sell its own "authorized generic" version until well after a generic drugmaker began selling its product.